Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Mountain Valley MD Holdings Inc C.MVMD

Alternate Symbol(s):  MVMDF

Mountain Valley MD Holdings Inc. is a Canada-based biotech company, which is focused on advancing solutions to optimize human, animal, and plant health. The Company is focused on implementation, licensing and reselling of key technologies and formulations, such as Quicksome oral formulation and delivery technologies, Quicksol solubility formulation technology, and Agrarius, a novel agricultural plant signaling technology. Quicksome technology utilizes proprietary formulations and stabilizing molecules to encapsulate and formulate active ingredients into efficient product formats. Quicksol technology covers all solubilized macrocyclic lactones that could be applied in multiple viral applications that could impact human and animal health globally. Agrairus agricultural plant signaling technology is used as application to agricultural crops to naturally increase yields, reduce fertilizer usage, and enhance general resilience to pests and climate change.


CSE:MVMD - Post by User

Comment by UterRebornon Jul 08, 2021 9:34pm
198 Views
Post# 33519501

RE:RE:Cold chain news

RE:RE:Cold chain newsSome thoughts on the cold chain results. Obviously everyone wanted to see 100% success across the 3 serotypes, but the results are very encouraging. To get 100% success for the 2nd serotype on the 1st attempt is impressive given the uncertainty of R&D. Also, I am not an expert, but given the 30 degree success, I suspect serotypes 1&3 require something between a tweek and a modification, rather than a complete process redesign.
Another point is that even if this IPV test  was 100% successful, this would not solve ALL of cold chain. IPV is a category C in terms of difficulty to break cold chain (which is mid range). MVMD would still have to prove out Category A&B samples to claim ALL of cold chain. Likely they would need some process changes anyway to achieve this. A good question for Dennis would be is this part of the 2 year agreement with the FDA?
<< Previous
Bullboard Posts
Next >>